Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Antimicrobial Stewardship —Treatment optimization under antibiotics appropriate use policy in ChinaRelease Date:Research Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Title Grant Type Focus Area Country Application Due Date Transition of Care in VTERelease Date:Anticoagulation Education - NVAF or VTERelease Date:Review Process:Achievement of Treat-to-Target in Rheumatoid ArthritisRelease Date:Improving Care of Chronic Pain- Physician Groups and Health SystemsRelease Date:Facilitation of the Diagnosis of Rheumatoid ArthritisRelease Date:Pfizer and NCCN: Metastatic Breast CancerRelease Date:Pediatric Immunization Series CompletionRelease Date:Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic ArthritisRelease Date:Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk PatientsRelease Date:Pfizer and American Academy of Dermatology (AAD): Patient Access to CareRelease Date:Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid ArthritisRelease Date: